WO2005085447A1 - β-フルクトフラノシダーゼ変異体 - Google Patents
β-フルクトフラノシダーゼ変異体 Download PDFInfo
- Publication number
- WO2005085447A1 WO2005085447A1 PCT/JP2005/003787 JP2005003787W WO2005085447A1 WO 2005085447 A1 WO2005085447 A1 WO 2005085447A1 JP 2005003787 W JP2005003787 W JP 2005003787W WO 2005085447 A1 WO2005085447 A1 WO 2005085447A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- substitution
- acid residue
- group
- seq
- Prior art date
Links
- 108010051210 beta-Fructofuranosidase Proteins 0.000 title claims abstract description 26
- CHUGKEQJSLOLHL-UHFFFAOYSA-N 2,2-Bis(bromomethyl)propane-1,3-diol Chemical compound OCC(CO)(CBr)CBr CHUGKEQJSLOLHL-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 235000011073 invertase Nutrition 0.000 title claims abstract description 25
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 76
- 230000035772 mutation Effects 0.000 claims abstract description 51
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 3
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 3
- 150000001413 amino acids Chemical group 0.000 claims description 74
- 238000006467 substitution reaction Methods 0.000 claims description 55
- 235000001014 amino acid Nutrition 0.000 claims description 41
- 229940024606 amino acid Drugs 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 36
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 33
- 229930006000 Sucrose Natural products 0.000 claims description 19
- 239000005720 sucrose Substances 0.000 claims description 19
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 18
- -1 aromatic amino acid Chemical class 0.000 claims description 15
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 14
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 14
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 14
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 14
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 11
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 10
- 239000004472 Lysine Substances 0.000 claims description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 9
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 9
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 9
- 229930182817 methionine Natural products 0.000 claims description 9
- 239000004475 Arginine Substances 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 7
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 7
- 229960000310 isoleucine Drugs 0.000 claims description 7
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 6
- 235000003704 aspartic acid Nutrition 0.000 claims description 6
- 235000013922 glutamic acid Nutrition 0.000 claims description 6
- 239000004220 glutamic acid Substances 0.000 claims description 6
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 claims description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- 235000009582 asparagine Nutrition 0.000 claims description 4
- 229960001230 asparagine Drugs 0.000 claims description 4
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 150000001510 aspartic acids Chemical class 0.000 claims 1
- 150000002307 glutamic acids Chemical class 0.000 claims 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 claims 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 23
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 23
- VAWYEUIPHLMNNF-OESPXIITSA-N 1-kestose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VAWYEUIPHLMNNF-OESPXIITSA-N 0.000 description 18
- GIUOHBJZYJAZNP-DVZCMHTBSA-N 1-kestose Natural products OC[C@@H]1O[C@](CO)(OC[C@]2(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)O[C@@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O GIUOHBJZYJAZNP-DVZCMHTBSA-N 0.000 description 18
- VAWYEUIPHLMNNF-UHFFFAOYSA-N kestotriose Natural products OC1C(O)C(CO)OC1(CO)OCC1(OC2C(C(O)C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 VAWYEUIPHLMNNF-UHFFFAOYSA-N 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 12
- FLDFNEBHEXLZRX-DLQNOBSRSA-N Nystose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(O[C@@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FLDFNEBHEXLZRX-DLQNOBSRSA-N 0.000 description 11
- FLDFNEBHEXLZRX-UHFFFAOYSA-N nystose Natural products OC1C(O)C(CO)OC1(CO)OCC1(OCC2(OC3C(C(O)C(O)C(CO)O3)O)C(C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 FLDFNEBHEXLZRX-UHFFFAOYSA-N 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 5
- 229920001542 oligosaccharide Polymers 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 241000228143 Penicillium Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000002966 varnish Substances 0.000 description 3
- 108700026220 vif Genes Proteins 0.000 description 3
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 1
- QNTKVQQLMHZOKP-NEJDVEAASA-N (2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-2-[[(2r,3s,4s,5r)-2-[[(2r,3s,4s,5r)-2-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]- Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QNTKVQQLMHZOKP-NEJDVEAASA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- BFMIRJBURUXDRG-DLOVCJGASA-N Ala-Phe-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 BFMIRJBURUXDRG-DLOVCJGASA-N 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- NXTYATMDWQYLGJ-BQBZGAKWSA-N Cys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CS NXTYATMDWQYLGJ-BQBZGAKWSA-N 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 240000008892 Helianthus tuberosus Species 0.000 description 1
- 235000003230 Helianthus tuberosus Nutrition 0.000 description 1
- 101000619708 Homo sapiens Peroxiredoxin-6 Proteins 0.000 description 1
- 238000012218 Kunkel's method Methods 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 108090000913 Nitrate Reductases Proteins 0.000 description 1
- 102100022239 Peroxiredoxin-6 Human genes 0.000 description 1
- SRILZRSXIKRGBF-HRCADAONSA-N Phe-Met-Pro Chemical compound CSCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N SRILZRSXIKRGBF-HRCADAONSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000985694 Polypodiopsida Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000122799 Scopulariopsis Species 0.000 description 1
- 241000825258 Scopulariopsis brevicaulis Species 0.000 description 1
- DKKGAAJTDKHWOD-BIIVOSGPSA-N Ser-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N)C(=O)O DKKGAAJTDKHWOD-BIIVOSGPSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- GINJFDRNADDBIN-FXQIFTODSA-N bilanafos Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCP(C)(O)=O GINJFDRNADDBIN-FXQIFTODSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 101150095344 niaD gene Proteins 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/18—Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01026—Beta-fructofuranosidase (3.2.1.26), i.e. invertase
Definitions
- the present invention relates to a ⁇ -fructofuranosidase mutant that selectively and efficiently generates a specific fratatooligosaccharide from sucrose, and more particularly, to a ⁇ -fructofruit that efficiently produces 1-kestose.
- the present invention relates to a furanosidase mutant and a j8-fructo furanosidase mutant that efficiently produces nystose.
- fratato-oligosaccharides are oligosaccharides in which one to three molecules of fructose are linked to fructose of sucrose at positions C1 and C2
- the technology to produce large quantities from sucrose using the reaction has been established and is industrially produced.
- the j8-fructofuranosidase currently used for industrial production of fratatooligosaccharides uses intracellular j8-fructofuranosidase derived from Aspergillus niger.
- the gene encoding the 13-fructofuranosidase is disclosed in WO97Z34004.
- the j8-fructofuranosidase produces fratato-oligosaccharide as a mixture of 1-kestose, nystose and 1-fructosylnystose, and fructo-oligosaccharide is manufactured and provided as a syrup or powder of an oligosaccharide mixture.
- j8-fructofuranosidase that can selectively and efficiently produce 1-kestose or nystose as a single component is obtained, the following utility exists.
- the enzyme used in this method As the characteristics of the enzyme used in this method, a high conversion rate of sucrose to 1-kestose and a low production amount of nystose are required by industrial production methods. Similarly, when -stose is produced as a single component, the industrial conversion method requires that the conversion rate to nystose is high and that 1 the amount of fructosyl nystose produced is low. ing.
- An object of the present invention is to provide a j8-fructofuranosidase mutant whose reaction characteristics are improved so as to be suitable for production of a single component of a fratatooligosaccharide, for example, 1-kestose or -stose, and its gene. .
- the present inventors have determined that a j8-fructofuranosidase mutant in which an amino acid residue at a specific position in the amino acid sequence of SEQ ID NO: 2 has been substituted with another amino acid residue is a 1-kestose or a ha-stose. It has been found that it has reaction characteristics suitable for the production of
- the mutant j8-fructofuranosidase according to the present invention is advantageous in that a single component of a fratatooligosaccharide can be industrially produced more easily and inexpensively than in the past.
- FIG. 1 is a diagram showing an example in which the amino acid sequence of SEQ ID NO: 2 and homologs thereof are aligned.
- the upper row shows the amino acid sequence of J8-fructofuranosidase from AikgE (SEQ ID NO: 2)
- the middle row shows the amino acid sequence of ⁇ -fructofuranosidase from S. brevicaulis (SEQ ID NO: 6)
- the lower row shows the amino acid sequence of P. roaueforiti.
- 1 shows the amino acid sequence of ⁇ -fructofuranosidase (SEQ ID NO: 4).
- the numbers in the figure represent the amino acid numbers when the ⁇ terminus of A ⁇ JlkgE is the first.
- the part indicated by the frame indicates a specific mutation part.
- FIG. 2 is a continuation of the amino acid sequence of FIG.
- the variants according to the first and second aspects of the present invention are those in which a mutation has been introduced into at least one of the specific amino acid residues of the amino acid sequence set forth in SEQ ID NO: 2 and homologs thereof.
- the position of the amino acid residue into which the mutation is introduced corresponds to the amino acid residue number in the amino acid sequence of SEQ ID NO: 2.
- mutant means substitution, deletion, and insertion.
- substitution means that a specific amino acid residue has been removed and another amino acid residue has been inserted at the same position.
- “Insertion” means that one or more amino acid residues are inserted before or after a specific amino acid residue, specifically, a specific amino acid residue. It means that one or more, preferably one or several, amino acid residues are bonded to the a carboxyl group or the a amino group of the amino acid residue.
- the number of specific mutations introduced into the amino acid sequence of SEQ ID NO: 2 and its homologue is as follows: although not particularly limited, it can be one or several, one to three, or one or two.
- the mutation introduced into the amino acid sequence of SEQ ID NO: 2 and a homolog thereof are preferably substitutions.
- the amino acid sequence represented by SEQ ID NO: 2 and its homologues at positions 62, 122, 128, 165, 221, 395, and 550 is preferably as follows.
- the mutant according to the first aspect of the present invention at least one of the amino acid residues of Nos. 170, 300, 313, and 386 of the amino acid sequence set forth in SEQ ID NO: 2 and homologs thereof
- the group may further have a mutation, preferably a substitution.
- the j8-fructofuranosidase having these mutations is advantageous in that 1-kestose can be selectively and efficiently produced (see, for example, WO99Z13059).
- the amino acid sequence represented by SEQ ID NO: 2 and a homolog thereof can be introduced at positions 170, 300, 313, and 386.
- the exchange is preferably as follows.
- preferred multiple mutations that can be introduced into the amino acid sequence of SEQ ID NO: 2 and its homologue include the amino acid residue at position 165; And a triple mutation of the amino acid residue at position 313, more preferably a triple substitution, and particularly preferably, a group power of the amino acid residue at position 165, which is tributophan, phenylalanine, and tyrosine.
- Substitution with the selected aromatic amino acid (most preferably substitution with phenylalanine), and substitution of amino acid residue 300 with the selected amino acids of tryptophan, phenylalanine, tyrosine and balinka (Most preferably, substitution for phosphorus) and the group force of amino acid residue 313, which is lysine, arginine, and histidine.
- substitution of groups of amino acids include also a triple substitution with force.
- the substitution introduced into the amino acid residues at positions 40, 379, and 381 of the amino acid sequence of SEQ ID NO: 2 and a homolog thereof is preferably Is as follows.
- the term "homolog” refers to at least one Or an amino acid sequence represented by SEQ ID NO: 2 having a plurality of mutations and having ⁇ -fructofuranosidase activity.
- the number of mutations can be one to several, or one, two, three, or four.
- whether or not a homologue has the / 3 fructofuranosidase activity is evaluated, for example, by allowing a protein having the amino acid sequence to act on a substrate and detecting a reaction product. For example, it can be evaluated according to the method described in Example 2.
- the position of the specific mutation according to the present invention in the homologue is determined based on the amino acid sequence of SEQ ID NO: 2 and the amino acid residue number of SEQ ID NO: 2 corresponding to the homologue.
- the "mutation of the 62nd amino acid residue” in the homologue means the homologue corresponding to the 62nd amino acid residue of the amino acid sequence of SEQ ID NO: 2 which is not the mutation of the 62nd amino acid residue of the homologue.
- the alignment of the amino acid sequence of SEQ ID NO: 2 with the homolog can be performed using analysis software for examining sequence identity. Needless to say, such software is well known and can be appropriately selected and used by those skilled in the art. For example, the BLAS method (Basic local alignment search tool; Altschul, S.. Et al.,
- J. Mol. Biol., 215, 403-410 (1990) can be used to align the amino acid sequence of SEQ ID NO: 2 with the homolog to determine the corresponding amino acid residue.
- homologues include one or more (eg, one to several, or one, two, three, or four) mutations that do not affect the / 3 fructofuranosidase activity.
- the amino acid sequence described in SEQ ID NO: 2 is exemplified.
- examples of the “mutation that does not affect the activity” include conservative substitution.
- Constant substitution refers to the replacement of one or more amino acid residues with another, chemically similar amino acid residue without substantially altering the activity of the protein. For example, there is a case where a certain hydrophobic residue is substituted with another hydrophobic residue, and a case where a certain polar residue is replaced with another polar residue having the same charge.
- Functionally similar amino acids that can make such substitutions are known in the art for each amino acid. It is known. Specific examples include non-polar (hydrophobic) amino acids such as alanine, phosphine, isoleucine, leucine, proline, tryptophan, phenylalanine, and methionine.
- Examples of polar (neutral) amino acids include glycine, serine, threonine, tyrosine, dartamine, asparagine, and cysteine.
- Examples of positively charged (basic) amino acids include anoreginin, histidine, and lysine.
- Examples of negatively charged (acidic) amino acids include aspartic acid and glutamic acid.
- Examples of the "homolog” also include j8-fructofuranosidase produced by a microorganism belonging to the genus Aspergillus, Penicillium and Scopulariopsis.
- j8-fructofuranosidase produced by a microorganism belonging to the genus Aspergillus, Penicillium and Scopulariopsis.
- ⁇ -funorectofurano derived from Aspergillus niger Among ferns ⁇ -fructofuranosidase from Penicillium roaueforti and ⁇ -fructofuranosidase from ScoDulariopsis brevicaulis are mentioned.
- Examples of j8-fructofuranosidase derived from Penicillium roaueforti include a protein (SEQ ID NO: 4) having the amino acid sequence of SEQ ID NO: 1 in W099Z13059.
- examples of j8-fructofuranosidase derived from ScoDulariopsis brevicaulis include a protein having the amino acid sequence of SEQ ID NO: 3 in WO99Z13059 (SEQ ID NO: 6).
- the DNA sequence encoding it is easily determined by referring to a so-called codon table. Therefore, various amino acid sequences of SEQ ID NO: 1 into which the specific mutation according to the present invention has been introduced and homologs thereof, for example, various amino acid sequences of SEQ ID NOs: 2, 4, and 6 into which the specific mutation according to the present invention has been introduced, The DNA sequence can be appropriately selected. Therefore, the specific mutation according to the present invention has been introduced.
- the DNA sequence encoding the fructofuranosidase mutant has a DNA mutation corresponding to the specific amino acid mutation according to the present invention.
- 8-fructofuranosidase gene A DNA sequence which has the same DNA sequence except that codons having the degenerate relationship are used, and which encodes a ⁇ -fructofuranosidase mutant.
- the DNA sequence encoding the amino acid sequence of SEQ ID NO: 2, 4, and 6 in which the specific mutation according to the present invention has been introduced refers to SEQ ID NOs: 1, 3, and 5 having one or more mutations described in Table 3 described below.
- 5 Not only the DNA sequence of the present invention but also a DNA sequence which has the same DNA sequence except that the degenerate codons are used and encodes a j8-fructofuranosidase mutant.
- ⁇ 8-fructofuranosidase mutants can be produced by recombinant DNA technology, polypeptide synthesis technology, and the like. If recombinant DNA technology is used, DNA that encodes
- 8-fructofuranosidase eg, the DNA sequence of SEQ ID NO: 1, 3, or 5
- a method for introducing a site-specific mutation of a gene a method well known to those skilled in the art such as a gapped duplex method and a Kunkel method can be used. These methods can be used to generate mutations at specific sites in the DNA encoding j8-fructofuranosidase.
- a commonly used method such as an error-blown PCR method can be employed.
- the nucleotide sequence of the DNA after the mutation treatment can be confirmed by the chemical modification method of Maxam's Gilbert, dideoxynucleotide chain termination method, etc., and the amino acid sequence of the ⁇ -fructofuranosidase mutant It can be decoded from the sequence.
- the ⁇ 8-fructofuranosidase mutant is a recombinant DNA fragment that is linked to a DNA molecule, particularly a DNA expression vector, that is capable of replicating and expressing the gene in host cells. It can be prepared by preparing a vector, introducing the recombinant vector into a host to obtain a transformant, and culturing the transformant under appropriate culture conditions.
- the vector used in the present invention can be appropriately selected from viruses, plasmids, cosmid vectors and the like in consideration of the type of host cell used.
- host When the vesicle is Escherichia coli, pUC and pBR plasmids, for Bacillus subtilis, pUB plasmid, and for yeast, YEp, YRp and YCp plasmid vectors.
- a plasmid can be used as a recombinant vector.
- the plasmid preferably contains a transformant selectable marker.
- a drug resistance marker or an auxotrophic marker can be used.
- Preferred examples thereof include an ampicillin resistance gene, a kanamycin resistance gene, a tetracycline resistance gene when the host cell used is a bacterium, and a tryptophan synthesis gene (TRP1) and a peracil synthesis gene (URA3) when the host cell is a yeast.
- LEU2 leucine synthesis gene
- Hyg hygromycin resistance gene
- Bar bialaphos resistance gene
- niaD nitrate reductase gene
- the DNA molecule as the expression vector according to the present invention includes a DNA sequence required for expression of the mutant gene, for example, a transcription control signal such as a promoter, a transcription initiation signal, a ribosome binding site, a translation termination signal, and a transcription termination signal; It preferably has a translation control signal and the like.
- a transcription control signal such as a promoter, a transcription initiation signal, a ribosome binding site, a translation termination signal, and a transcription termination signal; It preferably has a translation control signal and the like.
- promoter not only a promoter that can function in a host contained in the inserted fragment, but also a promoter such as ratatosupoperon (lac) and tryptophan operon (trp) in Escherichia coli, and an alcohol dehydrogenase in yeast Promoters such as the gene (ADH), acid phosphatase gene (PHO), galactose gene (GAL) and dali cellaldehyde triphosphate dehydrogenase gene (GPD); ) Can be preferably used.
- ADH gene
- PHO acid phosphatase gene
- GAL galactose gene
- GPD dali cellaldehyde triphosphate dehydrogenase gene
- any host can be used as long as a host vector system has been established, and preferably, mold and yeast are used.
- the transformant obtained by the transformation of the host cell is cultured under appropriate conditions, and the resulting culture broth is subjected to fractionation and purification of the enzyme by a common method to obtain j8-fructofuranofurano.
- a sidase variant can be obtained.
- the host is Bacillus subtilis, yeast, or mold, it is also advantageous to use a secretory vector to secrete the recombinant j8-fructofuranosidase outside the cells.
- the mutant according to the present invention produced from the transformant can be obtained as follows.
- the First the above-mentioned host cells are cultured under appropriate conditions, and a culture supernatant or cells are obtained from the resulting culture by a known method, for example, centrifugation. In the case of cells, this is suspended in an appropriate buffer, the cells are disrupted by freeze-thawing, sonication, grinding, etc., and the cell extract containing the recombinant enzyme is centrifuged or filtered. obtain.
- the enzyme can be purified by appropriately combining conventional separation and purification methods. For example, methods utilizing differences in heat resistance such as heat treatment, methods utilizing differences in solubility such as salt precipitation and solvent precipitation, and methods such as dialysis, ultrafiltration, gel filtration and SDS polyacrylamide gel electrophoresis. Methods that use different molecular weights, methods that use charge differences such as ion-exchange chromatography, methods that use specific affinities such as affinity chromatography, hydrophobic chromatography, and reverse-phase chromatography. Examples of the method include a method using the difference in hydrophobicity as described above, and a method using a difference in isoelectric point such as isoelectric focusing.
- the present invention there is provided a method for producing a fura-oligosaccharide using the transformant according to the present invention or the ⁇ -fructofuranosidase mutant according to the present invention. That is, the method for producing a fratatooligosaccharide according to the present invention is carried out by contacting the transformant according to the present invention or the
- the mode of contacting the transformant according to the present invention or the ⁇ -fructofuranosidase mutant according to the present invention with sucrose and the conditions thereof are not particularly limited as long as the mutant can act on sucrose.
- Preferred embodiments for contacting in a solution are as follows. That is, the concentration of sucrose to be used may be appropriately selected in consideration of the specific activity of the enzyme, the reaction temperature, etc., as long as the used sugar can be dissolved, but should be in the range of 5-80%. It is common and preferably in the range of 30-70%.
- the reaction temperature and ⁇ conditions for the reaction between the sugar and the enzyme are preferably performed under the optimal conditions for the mutant, for example, generally at about 30-80 ° C and pH 4-10. And preferably 40-70. C, pH5-7.
- the degree of purification of the mutant can be appropriately selected, and the culture supernatant of the transformant or the cell crushing ability can be used as it is as the crude enzyme.
- the crude enzyme Was It may be used as a purified enzyme.
- the enzyme may be used as an enzyme isolated and purified through various purification means.
- the enzyme may be contacted with sucrose in a state of being immobilized on a carrier according to a conventional method.
- the produced fratatooligosaccharide can be obtained by purifying the reaction solution according to a known method. For example, there is a method in which the enzyme is deactivated by heating, then decolorized with activated carbon, and further desalted with an ion exchange resin.
- the present invention provides a method for selectively producing 1-kestose. That is, according to the present invention, a transformant capable of expressing the
- the mutant of the second embodiment of the present invention is used for the preparation of a fratatooligosaccharide, the amount of nystose produced increases and the amount of 1-kestose produced is suppressed. Therefore, according to the present invention, there is provided a method for selectively producing a steel. That is, according to the present invention, a transformant capable of expressing the polynucleotide encoding the
- the random mutation was introduced into the j8-fructofuranosidase gene using a commercially available PCR muta genesis kit (Gene Morph, Stratagene) as follows.
- the j8-fructofuranosidase gene derived from ATCC 20611 strain G ⁇ nkgE) was used as type I DNA.
- the plasmid pAW20-Hyg described in WO97 / 34004 was used.
- the PCR reaction solution consisted of 5 ⁇ l of 1 ⁇ 1, 40 mM dNTP 1 ⁇ 1, 10-fold concentration buffer
- 5 -GCGAATTCATGAAGCTCACCACTACCA-3, (N-terminal) (SEQ ID NO: 7) and 5'-GCGGATCCCGGTCAATTTCTCT-3 '(C-terminal) (SEQ ID NO: 8) DMSO 51 and sterilized water 36 ⁇ l were calored to obtain 501.
- the reaction was pretreated at 94 ° C for 2 minutes, followed by incubation at 94 ° C for 1 minute (denaturation step), 50 ° C for 2 minutes (annealing step), 72 ° C for 2.5 minutes (extension step). 30 cycles were performed.
- the obtained transformant was placed in SD-GF medium (0.67% yeast nitrogen base w / o amino acids ⁇ 2% sucrose 1 ⁇ ⁇ s, 2% casamino acids ⁇ 50 ⁇ g / ml ⁇ lacil) at 30 ° C. After culturing for 3 days, a j8-fructofuranosidase mutant was obtained.
- the DNA base sequence was analyzed.
- a sequencing reaction was performed using a DNA sequence kit manufactured by Pharmacia.
- the sample after the reaction was analyzed using a DNA sequencer (ALFred) of Pharmacia to obtain the nucleotide sequence of each DNA fragment.
- the final nucleotide sequence was obtained using DNA analysis software (DNASIS, Hitachi Software Engineering Co., Ltd.), and the mutation point into which the random mutation was introduced was determined.
- Table 2 Fructofuranosidase mutants with increased nystose production and reduced 1-kestose production
- G F 4 1-Funolecto sinorenistose The resulting mutations and the corresponding DNA sequences were as follows. Underline indicates mutated DNA.
- V165F obtained in Example 2 with G300V and H313K described in WO97Z34004
- the combined triple substitution mutant was prepared by site-directed mutagenesis. Specifically, a plasmid was prepared by inserting the ⁇ -fructofuranosidase gene into which the mutation of V165F prepared in Examples 1 and 2 was introduced into the EcoRI-BamHI site of pUC118 (Takara Shuzo). Next, mutations of G300V and H313K were sequentially introduced in the same manner as in Example D8 of WO97 / 34004. As a result of examining the DNA base sequence in the same manner as in Example 2, it was confirmed that only the target base sequence was replaced.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006510750A JPWO2005085447A1 (ja) | 2004-03-04 | 2005-03-04 | β−フルクトフラノシダーゼ変異体 |
US10/591,751 US7655449B2 (en) | 2004-03-04 | 2005-03-04 | β-fructofuranosidase variants |
EP05720059A EP1726655A4 (en) | 2004-03-04 | 2005-03-04 | BETA-fructofuranosidase MUTANT |
CA002558593A CA2558593A1 (en) | 2004-03-04 | 2005-03-04 | .beta.-fructofuranosidase variants |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004060426 | 2004-03-04 | ||
JP2004-060426 | 2004-03-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005085447A1 true WO2005085447A1 (ja) | 2005-09-15 |
Family
ID=34918019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/003787 WO2005085447A1 (ja) | 2004-03-04 | 2005-03-04 | β-フルクトフラノシダーゼ変異体 |
Country Status (5)
Country | Link |
---|---|
US (1) | US7655449B2 (ja) |
EP (1) | EP1726655A4 (ja) |
JP (1) | JPWO2005085447A1 (ja) |
CA (1) | CA2558593A1 (ja) |
WO (1) | WO2005085447A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010148419A (ja) * | 2008-12-25 | 2010-07-08 | Japan Agengy For Marine-Earth Science & Technology | 新規なβ−フルクトフラノシダーゼ、その製造方法及びその利用 |
WO2016017774A1 (ja) * | 2014-08-01 | 2016-02-04 | 物産フードサイエンス株式会社 | 改良型β-フルクトフラノシダーゼ |
WO2016143873A1 (ja) * | 2015-03-11 | 2016-09-15 | 物産フードサイエンス株式会社 | 改良型β-フルクトフラノシダーゼ |
CN108588058A (zh) * | 2018-04-28 | 2018-09-28 | 南京工业大学 | β-呋喃果糖苷酶突变体及其应用 |
WO2023058637A1 (ja) * | 2021-10-04 | 2023-04-13 | 京都府公立大学法人 | 改良型β-フルクトフラノシダーゼ |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU24158B1 (es) | 2012-09-18 | 2016-03-30 | Ct De Ingeniería Genética Y Biotecnología | Método de obtención de 1-kestosa |
US20160244791A1 (en) * | 2013-09-26 | 2016-08-25 | The University Of Florida Research Foundation, Inc. | Methods and enzymes for producing hydroxymethylfurfural |
CN105899661B (zh) * | 2013-12-27 | 2020-02-21 | 物产食品科技股份有限公司 | 改良型β-呋喃果糖苷酶 |
EP3201335B1 (en) | 2014-10-02 | 2019-09-04 | Stellenbosch University | A modified b-fructofuranosidase for fructooligosaccharide production |
KR102402632B1 (ko) * | 2019-10-31 | 2022-05-26 | 주식회사 삼양사 | 케스토스-함유 프락토올리고당 제조방법 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997034004A1 (fr) * | 1996-03-11 | 1997-09-18 | Meiji Seika Kaisha, Ltd. | β-FRUCTOFURANNOSIDASE ET SON GENE, PROCEDE D'ISOLEMENT DU GENE DE β-FRUCTOFURANNOSIDASE, SYSTEME POUR LA PRODUCTION DE β-FRUCTOFURANNOSIDASE, ET VARIANT DE β-FRUCTOFURANNOSIDASE |
WO1999013059A1 (en) * | 1997-09-10 | 1999-03-18 | Meiji Seika Kaisha, Ltd. | β-FRUCTOFURANOSIDASE AND GENE THEREOF |
JP2004242528A (ja) * | 2003-02-12 | 2004-09-02 | National Agriculture & Bio-Oriented Research Organization | 結晶1−ケストース製造に用いるβ−フルクトフラノシダーゼの選抜法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004078966A1 (ja) * | 2003-03-03 | 2004-09-16 | Meiji Seika Kaisha, Ltd. | フラクトオリゴ糖蓄積トランスジェニック植物及びその作出方法 |
-
2005
- 2005-03-04 JP JP2006510750A patent/JPWO2005085447A1/ja active Pending
- 2005-03-04 EP EP05720059A patent/EP1726655A4/en not_active Withdrawn
- 2005-03-04 US US10/591,751 patent/US7655449B2/en not_active Expired - Fee Related
- 2005-03-04 WO PCT/JP2005/003787 patent/WO2005085447A1/ja active Application Filing
- 2005-03-04 CA CA002558593A patent/CA2558593A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997034004A1 (fr) * | 1996-03-11 | 1997-09-18 | Meiji Seika Kaisha, Ltd. | β-FRUCTOFURANNOSIDASE ET SON GENE, PROCEDE D'ISOLEMENT DU GENE DE β-FRUCTOFURANNOSIDASE, SYSTEME POUR LA PRODUCTION DE β-FRUCTOFURANNOSIDASE, ET VARIANT DE β-FRUCTOFURANNOSIDASE |
WO1999013059A1 (en) * | 1997-09-10 | 1999-03-18 | Meiji Seika Kaisha, Ltd. | β-FRUCTOFURANOSIDASE AND GENE THEREOF |
JP2004242528A (ja) * | 2003-02-12 | 2004-09-02 | National Agriculture & Bio-Oriented Research Organization | 結晶1−ケストース製造に用いるβ−フルクトフラノシダーゼの選抜法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1726655A4 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010148419A (ja) * | 2008-12-25 | 2010-07-08 | Japan Agengy For Marine-Earth Science & Technology | 新規なβ−フルクトフラノシダーゼ、その製造方法及びその利用 |
WO2016017774A1 (ja) * | 2014-08-01 | 2016-02-04 | 物産フードサイエンス株式会社 | 改良型β-フルクトフラノシダーゼ |
JP2016034273A (ja) * | 2014-08-01 | 2016-03-17 | 物産フードサイエンス株式会社 | 改良型β−フルクトフラノシダーゼ |
WO2016143873A1 (ja) * | 2015-03-11 | 2016-09-15 | 物産フードサイエンス株式会社 | 改良型β-フルクトフラノシダーゼ |
JPWO2016143873A1 (ja) * | 2015-03-11 | 2017-12-21 | 物産フードサイエンス株式会社 | 改良型β−フルクトフラノシダーゼ |
US10240136B2 (en) | 2015-03-11 | 2019-03-26 | B Food Science Co., Ltd. | β-fructofuranosidase |
CN108588058A (zh) * | 2018-04-28 | 2018-09-28 | 南京工业大学 | β-呋喃果糖苷酶突变体及其应用 |
CN108588058B (zh) * | 2018-04-28 | 2020-04-21 | 南京工业大学 | β-呋喃果糖苷酶突变体及其应用 |
WO2023058637A1 (ja) * | 2021-10-04 | 2023-04-13 | 京都府公立大学法人 | 改良型β-フルクトフラノシダーゼ |
Also Published As
Publication number | Publication date |
---|---|
US20080187970A1 (en) | 2008-08-07 |
US7655449B2 (en) | 2010-02-02 |
JPWO2005085447A1 (ja) | 2008-01-24 |
EP1726655A4 (en) | 2007-12-12 |
EP1726655A1 (en) | 2006-11-29 |
CA2558593A1 (en) | 2005-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005085447A1 (ja) | β-フルクトフラノシダーゼ変異体 | |
CA3083563A1 (en) | Gene-modified microorganism for producing 3-hydroxyadipic acid, .alpha.-hydromuconic acid, and/or adipic acid, and production method for said chemical products | |
JP5224572B2 (ja) | デキストラン生成酵素遺伝子、デキストラン生成酵素およびその製造方法、デキストランの製造方法 | |
KR101807507B1 (ko) | D-사이코스 3-에피머화 효소 및 염을 포함하는 d-사이코스 제조용 조성물 및 이를 이용한 d-사이코스의 제조 방법 | |
KR20140080282A (ko) | D-사이코스 3-에피머화 효소를 이용한 과당으로부터 사이코스의 제조방법 | |
CN116376875B (zh) | 耐热性提高的n-乙酰氨基葡萄糖苷酶突变体及其应用 | |
WO2018116266A1 (en) | D-psicose 3-epimerase mutant and uses thereof | |
JP2010273580A (ja) | 1−ケストースの結晶化母液の調製方法 | |
KR20160108375A (ko) | 개량형 β-프룩토프라노시다아제 | |
JP2023506154A (ja) | アルロースエピマー化酵素変異体、その製造方法及びそれを利用したアルロースの製造方法 | |
KR100576409B1 (ko) | 베타-프락토푸라노시다제 및 그의 유전자 | |
AU784466B2 (en) | Cyclic depsipeptide synthases, genes thereof and mass production system of cyclic depsipeptide | |
KR101708974B1 (ko) | 신규한 수크로스이성화효소 및 이의 제조방법 | |
JP2021536253A (ja) | 組換えレクチンタンパク質の調製のための改善されたプロセス | |
KR20190001934A (ko) | 기능성 감미료의 제조방법 | |
KR102232837B1 (ko) | 글루코실글리세롤 생산 활성을 가지는 신규한 폴리펩티드 및 이를 이용한 글루코실글리세롤 제조방법 | |
KR102254411B1 (ko) | 알룰로스 에피머화 효소 변이체, 이의 제조방법 및 이를 이용한 알룰로스의 제조방법 | |
KR20140111093A (ko) | 향상된 전환 활성을 가지는 l-아라비노스 이성화효소 변이체 및 이를 이용한 d-타가토스의 생산 방법 | |
CN113416725A (zh) | 一种重组硫酸软骨素酶abc-i蛋白及其制备方法与应用 | |
KR101778878B1 (ko) | 박테로이데스 속 미생물 유래의 gaba 생성 고활성 글루탐산탈탄산효소 및 이의 용도 | |
WO2023058637A1 (ja) | 改良型β-フルクトフラノシダーゼ | |
KR20160014818A (ko) | 변이된 수크로스이성화효소 및 이의 제조방법 | |
EP4257689A1 (en) | Novel promoter variant for constitutive expression and use thereof | |
CN114990097B (zh) | L-天冬氨酸-α-脱羧酶突变体及其应用 | |
KR101222889B1 (ko) | 이중프로모터를 포함하는 발현 시스템 및 그 시스템을 이용한 유전자 과다 발현 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10591751 Country of ref document: US Ref document number: 2558593 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006510750 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005720059 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005720059 Country of ref document: EP |